Author details

Full Name

Michael I Nishimura

Affiliation

ORCID

Career Start Year

1988

Papers

127

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37000627	Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance.	Cell Rep	2023
37967375	Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior.		2023
35290663	Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.	Immunology	2022
36424374	A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometry.	Nature Communications	2022
35335089	Genetic Modification of T Cells for the Immunotherapy of Cancer.	Vaccines	2022
33614916	HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced TÂ cells.	Molecular Therapy - Oncolytics	2021
34172810	Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response.	Scientific Reports	2021
33524161	Human CD36 monocytes induce Foxp3 Â CD25 T cells with regulatory functions from CD4 and CD8 subsets.	Immunology	2021
31473851	Targeting Cancer with Genetically Engineered TCR T Cells.	Recent Results in Cancer Research	2020
31836878	Improved MHC II epitope prediction - a step towards personalized medicine.	Nature Reviews Clinical Oncology	2020
31669398	Late Events After CD-19 CAR-T Treatment.	Biology of Blood and Marrow Transplantation	2020
32937437	Identification of human CD4<sup>+</sup> T cell populations with distinct antitumor activity.	Sci Adv	2020
31307533	Transgenerational transfer of gene-modified T cells.	Journal for ImmunoTherapy of Cancer	2019
31595324	Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy.	Cancer Immunology, Immunotherapy	2019
31585951	Identification of a tumor-specific allo-HLA-restricted Î³Î´TCR.	Blood Adv	2019
30009548	Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.	Pigment Cell Melanoma Res	2019
30617019	Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.	Molecular Therapy	2019
30971427	Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells.	J Biol Chem	2019
30792401	Potassium channel activity controls breast cancer metastasis by affecting Î²-catenin signaling.	Cell Death and Disease	2019
29503203	Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.	Mol Ther	2018
29052782	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.	Cancer Immunol Immunother	2018
29885993	Activated human Foxp3 regulatory T cells produce membrane-bound TNF.	Cytokine	2018
29881824	Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.	Hepatology Communications	2018
30224695	T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability.	Nature Chemical Biology	2018
29396710	N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.	Cancer Immunol Immunother	2018
29350789	TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence.	J Leukoc Biol	2018
29264697	Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.	Cancer Immunol Immunother	2018
29180044	Cell intrinsic characteristics of human cord blood naÃ¯ve CD4T cells.	Immunology Letters	2018
29129787	CD38-NAD<sup>+</sup>Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.	Cell Metab	2018
29521881	Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.	Melanoma Research	2018
29152058	Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy.	Oncotarget	2017
28601925	Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-Î³ and multiple toll-like receptor agonists.	Cancer Immunology, Immunotherapy	2017
28388966	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.	J Hematol Oncol	2017
28550117	Comparative exploration of multidimensional flow cytometry software: a model approach evaluating T cell polyfunctional behavior.	Journal of Leukocyte Biology	2017
28634816	Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.	Cancer Immunol Immunother	2017
28573185	HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer.	Mol Ther Oncolytics	2017
28572406	How an alloreactive T-cell receptor achieves peptide and MHC specificity.	Proceedings of the National Academy of Sciences of the United States of America	2017
28830671	Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer.	Molecular Therapy	2017
28919985	Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms.	Oncoimmunology	2017
27742673	Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.	Cancer Res	2016
27197263	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.	Cancer Research	2016
26842125	TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.	Cancer Immunol Immunother	2016
26884163	How structural adaptability exists alongside HLA-A2 bias in the human Î±Î² TCR repertoire.	Proc Natl Acad Sci U S A	2016
27142958	FAK Kinase Activity Is Required for the Progression of c-MET/Î²-Catenin-Driven Hepataocellular Carcinoma.	Gene Expr	2016
26921345	Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.	J Leukoc Biol	2016
27138532	Strategies to genetically engineer T cells for cancer immunotherapy.	Cancer Immunology, Immunotherapy	2016
26824221	Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin.	Pigment Cell and Melanoma Research	2016
26906089	Differential scanning fluorimetry based assessments of the thermal and kinetic stability of peptide-MHC complexes.	Journal of Immunological Methods	2016
27466285	Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.	Cancer Res	2016
27750220	Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control.	Oncotarget	2016